Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
AI and Precision medicine conference in San Diego, days before AACR!
SAN DIEGO—On opening day of the 31st annual Precision Med TRI-CON, hosted by Cambridge Healthtech Institute and held this week in San Diego, CA, Eric Topol, MD, renowned cardiologist and director of the Scripps Research Translational Institute, emphasized that the use of artificial intelligence (AI) will be “the biggest transformation in the history of medicine,” citing the launch of ChatGPT as the hallmark of a new phase of generative AI applications.
Worth re-reading the statement from the AVA6000 phase 1a clinical trial progress: the company said :"We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION™ platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."
Note " further detailed update ", the company is referring to both clinical and commercial progress?
With the news embargo of the above till the 9/4, we have have very few trading days left, before lift off in San Diego.
Gives Novo even more cash to acquire further!
AVCT Therapeutics would fit nicely.
:
Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by Astra Zeneca.
Deal value up to US$1.05 billion
Novo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt's largest investor
Acquisition validates Novo Holdings' strategy to identify and invest long term in high quality European biotech companies
On the exchange, the term "shortly "can/ could be in the next couple of weeks.
Never mind, let us just focus on the "new"shareholder list, a well known European life science fund, could be anything from Allianz to Novartis. How convenient in front of the AACR presentation .
Https://accsindia.org/adcom2022/
BMY and JNJ
Meanwhile AVA6000 about to present shortly!
Ahead of ADCOM:
The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's and Bristol-Myers Squibb's cancer therapies as earlier treatments for blood cancer patients.
Staff reviewers said that the pattern of early deaths observed in patients treated with both the therapies in their respective trials raised uncertainty about their overall survival benefit.
The therapies - J&J's Carvykti and Bristol Myers' Abecma - are approved by the FDA to treat patients with multiple myeloma who have received at least four prior lines of treatment.
Back to business, in today's trading, with earlier NY hours- we have had est 300/ purchased over the last couple of hours and the buying will now accelerate and once again an attempt to break though 60-5p level and then fast track rest of the week, with more M&A State side as well. Lively couple of weeks pre AACR coming up.
Always good to load up during news embargo !
A familiar gentlemen now at the helm of Affyxell, wants to move things forward and have the compass firmly pointed on Wall street,one wonder what valuation Avacta really have for their no cost holding or are the Chinese going to buy their holding/acquire Affyxell before all that?
I do indeed know of their part ownership, as we should all do !
However it does not stop them researching Affimer.
We will still have an old fashioned Friday with size buyers moving it above 70, at Friday close .
More news before conference I suspect .